ライフサイエンスコーパス: intraductal

1 n (n = 27), biliary strictures (n = 10), and intraductal abnormalities (n = 7) was 96.3%, 90%, and 10

2 The presence of dilatation, strictures, and intraductal abnormalities was recorded.

3 Intraductal administration of PLD to neu-N mice caused r

4 ced by i.p. administration of cerulein or by intraductal administration of sodium taurocholate.

5 Local intraductal administration of the synthetic double stran

6 owing drug release in the mammary duct after intraductal administration overcomes the rapid ductal cl

7 Intraductal administration resulted in lower circulating

8 metal complex of CPX and Zinc (CPXZn) after intraductal administration was investigated.

9 l models indicate that PADI4 is critical for intraductal aggregate formation and that PADI4-deficienc

10 e biliary drainage, the beneficial effect of intraductal antibiotic prophylaxis was even more evident

11 Patients profiting most obviously from intraductal antimicrobials were those with secondary scl

12 We found that the intraductal approach is feasible for the study of the ea

13 Our objective was to explore an intraductal approach to studying breast cancer and preca

14 ANP was induced in rats by standardized intraductal bile acid infusion and cerulein hyperstimula

15 after testing, two were found to have occult intraductal breast cancers.

16 overexpression was identified in 22% of pure intraductal breast carcinomas and in 35% of breast CIS w

17 p53 overexpression were relatively common in intraductal breast carcinomas but were not observed in a

18 An analysis was performed of 270 intraductal breast carcinomas in 268 women from 10 insti

19 been identified in breast carcinoma in situ (intraductal breast carcinomas).

20 isease that exists in large-duct (often with intraductal calculi) or small-duct form.

21 lasia, inflammation, stromal overgrowth, and intraductal cancer-like lesions.

22 We were successful in intraductal cannulation and endoscopy in seven of the ni

23 to mouse submandibular glands is possible by intraductal cannulation and that reduction of either the

24 The malignant wounds included 4 intraductal carcinoma (33.33%) and 7 infiltrating ductal

25 the large cribriform pattern (94.7%) and the intraductal carcinoma (96%), were correctly detected by

26 re increasingly common in patients with pure intraductal carcinoma (DCIS).

27 Background Intraductal carcinoma (IDC) and invasive cribriform (Cr)

28 ggressive large cribriform pattern (LCP) and intraductal carcinoma (IDC) prostate cancer (PCa) at who

29 both invasive cribriform carcinoma (ICC) and intraductal carcinoma (IDC), is an aggressive histologic

30 icient to fulfil the diagnostic criteria for intraductal carcinoma (IDC).

31 Foci of intraductal carcinoma could be microdissected from 85 ca

32 PC, particularly to confirm the presence of intraductal carcinoma of the prostate (IDC-P), an aggres

33 commonly show the concurrent presence of the intraductal carcinoma of the prostate (IDCP) pathology,

34 tomic subtype associated with the aggressive intraductal carcinoma sub-histology and a fusion profile

35 ications were associated with more extensive intraductal carcinoma, more Her2/neu immunoreactivity, a

36 neficial than lumpectomy alone for localized intraductal carcinoma-in-situ (DCIS).

37 No LOH was seen in pure intraductal carcinomas (0/20 cases).

38 mas in situ and three low-grade invasive and intraductal carcinomas (2-5 mm).

39 uctal carcinomas, two mixed infiltrating and intraductal carcinomas, two infiltrating lobular carcino

40 For patients </= 55 years old, extensive intraductal component (EIC) was the next significant spl

41 78), and having a tumor without an extensive intraductal component (OR, 2.07; 95% CI, 1.81 to 2.37) w

42 LOH was detected in the intraductal component in 26 of these 30 cases.

43 iation therapy whether there is an extensive intraductal component or not.

44 An associated intraductal component was present in 59% of BABCs and 76

45 ss of Dpc4 expression was associated with an intraductal component which showed focal loss of Dpc4 ex

46 margins of excision, absence of an extensive intraductal component, nodal status, estrogen receptor s

47 ty because of their large size and prominent intraductal component.

48 had invasive ductal carcinoma with extensive intraductal component.

49 or invasive ductal carcinoma with extensive intraductal component.

50 obular cancers, or cancers with an extensive intraductal component.

51 All 79 of the intraductal components of the IPMNs strongly expressed D

52 Intraductal CPX NS administration was dose and time depe

53 ed to express specific genes into a "mammary intraductal DCIS" xenograft model.

54 racteristics, 2383 (38%) had noninfiltrating intraductal DCIS, and 2011 (32%) were treated with maste

55 endocrine beta-cells, while local pancreatic intraductal delivery of AAV6 showed the best efficiency

56 Upon intraductal delivery of sgRNA-encoding vectors, we could

57 l complete response (absence of invasive and intraductal disease in the breast and the axillary lymph

58 some lineage-tracing strategies suggest that intraductal endocrine cells cannot dynamically derive fr

59 mmary tumor virus-EZH2 virgin mice developed intraductal epithelial hyperplasia resembling the human

60 nd colocalization with beta-catenin in human intraductal epithelial hyperplasia, the earliest histolo

61 PMNs) are grossly visible (typically > 5 mm) intraductal epithelial neoplasms of mucin-producing cell

62 pancreaticoduodenectomy); all had dysplastic intraductal epithelium and chronic pancreatitis, whereas

63 In five women who had a focal intraductal filling defect, immediate stereotactic vacuu

64 specificity for strictures, dilatation, and intraductal filling defects (all choledocholithiasis) we

65 MRCP images for strictures, dilatation, and intraductal filling defects.

66 Intraductal glyceryl trilinoleate with or without the li

67 iant of bile duct carcinoma characterized by intraductal growth and better outcome compared with the

68 h or without MDE typically exhibit extensive intraductal growth but are slow to invade the periductal

69 ificantly higher than those in IDC, atypical intraductal hyperplasia, and normal breast epithelia adj

70 ed enhanced ductal branching, dilated ducts, intraductal hyperplasia, hyperplastic alveolar nodules a

71 se in lateral ductal branching and pervasive intraductal hyperplasia.

72 elevant doses of BPA increased the number of intraductal hyperplasias and ductal carcinomas in situ b

73 eoplastic foci, LOH occurred in two of eight intraductal hyperplasias but not in histologically norma

74 Microdissected foci of intraductal, infiltrating, and metastatic tumors were an

75 Acute pancreatitis was induced in rats by intraductal infusion of 3.5% sodium taurocholate.

76 njury may be decreased significantly with an intraductal infusion of chilled saline.

77 that "chemical pancreatectomy," a pancreatic intraductal infusion of dilute acetic acid solution, abl

78 ctivated duct cells by labeling them through intraductal infusion with a cell-tagging dye, CFDA-SE No

79 th a combination of caerulein and controlled intraductal infusion.

80 ere delivered into the mouse mammary teat by intraductal injection in the absence of surgical manipul

81 ration of AAV GCG-EGFP by intraperitoneal or intraductal injection led to EGFP expression selectively

82 CP was induced in Sprague-Dawley rats by an intraductal injection of 2% trinitrobenzene sulfonic aci

83 We evaluated induction of inflammation (by intraductal injection of [(14)C]sucrose and histological

84 Using intraductal injection of a lentivirus to deliver both an

85 Our results demonstrate that intraductal injection of adenovirus vectors provides a v

86 e divided into treatment groups and a single intraductal injection of CPX NS, CPX-Zn NS or CPX-Zn NPs

87 re readily induced to form mammary tumors by intraductal injection of RCAS (an ALV/A-derived vector)

88 designed to replicate the human variables by intraductal injection of the triglyceride glyceryl trili

89 CP was induced by intraductal injection of trinitrobenzene sulfonic acid i

90 CP was induced in rats by intraductal injection of trinitrobenzene sulfonic acid.

91 Compared with systemic administration, intraductal injection provides direct access to breast l

92 n cells transplanted into mammary glands via intraductal injection.

93 Modulation of DNA damage levels in vivo by intraductal injections of nucleosides or DNA damaging ag

94 Briefly, two days after 13762 Mat B III cell intraductal inoculation, rats were divided into treatmen

95 Intraductal instillation of an RCAS vector carrying the

96 nvasive neoplastic precursor, the pancreatic intraductal lesion (PIL).

97 ported to result in improved localization of intraductal lesions and may avoid surgery in women with

98 1B), and all 23 atypical papillary (PanIN-2) intraductal lesions expressed Dpc4.

99 opancreatography and balloon trawling of the intraductal lesions extracted necrotic tumour-like tissu

100 Ductoscopy identifies intraductal lesions in a high proportion of women with S

101 ma develops from histologically identifiable intraductal lesions that undergo a series of architectur

102 he results regarding density of extrahepatic intraductal lesions that were studied at BT were compare

103 kwave lithotripsy and/or pancreatoscopy with intraductal lithotripsy may be required.

104 nt ligands and pro-migratory genes, enabling intraductal macrophage infiltration and supporting regen

105 ne of the seven patients, a benign-appearing intraductal mass was identified at MR imaging; excisiona

106 as developed to define habitats in the tumor intraductal microenvironment based on oxygen diffusion d

107 During progression of prostate cancer, the intraductal microvessel density (IMVD) was also observed

108 , we characterized 115 patient-derived mouse-intraductal (MIND) DCIS models reflecting the full spect

109 ting tumor cell (CTC) populations in mammary intraductal (MIND) models.

110 or early dissemination in DCIS using a Mouse IntraDuctal model.

111 IPMNs are intraductal mucin-producing cystic neoplasms of the panc

112 Mucinous (intraductal mucinous neoplasm or mucinous cystic neoplas

113 Pancreatic cysts may be intraductal mucinous neoplasms, mucinous cystic neoplasm

114 ucinous cystic neoplasm (MCN), 29 pancreatic intraductal neoplasia (PanIN) and 8 IPMN-associated PDAC

115 Pancreatic intraductal neoplasia (PanIN) is thought to be the precu

116 11 antigen localizes to regions of prostatic intraductal neoplasia in paraffin-embedded sections.

117 small percentage of preneoplastic pancreatic intraductal neoplasia lesions lost rap1GAP expression, w

118 The proportion of women with intraductal neoplasia was slightly greater in the group

119 solid nodules, ductal hyperplasia, and mini-intraductal neoplasm and adenoma.

120 ancreatitis can be reduced experimentally by intraductal neurokinin-1 receptor antagonist and clinica

121 Intraductal oncocytic papillary neoplasms (IOPNs) of the

122 RKACA/B represent the diagnostic hallmark of intraductal oncocytic papillary neoplasms (IOPNs).

123 umpectomy specimens to determine presence of intraductal or invasive cancer.

124 ed for the Dpc4 protein (n = 50), all of the intraductal or noninvasive components strongly expressed

125 : A survey of women aged 20 to 79 years with intraductal or stage I and II breast cancer diagnosed be

126 Intraductal pancreatic injections in transgenic Oncopigs

127 cluding cystic tumors, endocrine tumors, and intraductal pancreatic mucinous neoplasms are included.

128 Experiences of the treatment of intraductal pancreatic mucinous neoplasms shed some ligh

129 s published large series on the treatment of intraductal pancreatic mucinous neoplasms.

130 tumors and the premalignant biliary lesions, intraductal papillary biliary neoplasms (IPBN), and Von

131 ontrol mice developed sporadic, macroscopic, intraductal papillary lesions with histologic and molecu

132 nts (40%), MRI revealed a pancreatic lesion: intraductal papillary mucinous neoplasia (14 patients, 3

133 n the rapid development of tumors resembling intraductal papillary mucinous neoplasia (IPMN), a precu

134 ive parameters predict malignant or invasive intraductal papillary mucinous neoplasia (IPMN).

135 ts, 25 clinical controls, and seven cases of Intraductal Papillary Mucinous Neoplasia (IPMN).

136 as (mPanIN) and promoted a high incidence of intraductal papillary mucinous neoplasia and active fibr

137 One patient had a synchronous intraductal papillary mucinous neoplasia and pancreatic

138 r pancreatic ductal adenocarcinoma and 2 for intraductal papillary mucinous neoplasia), while the rem

139 number of positive lymph nodes, a context of intraductal papillary mucinous neoplasia, and vascular r

140 transplanted PDLOs with mutant GNAS lead to intraductal papillary mucinous neoplasia-like structures

141 BACKGROUND & AIMS: Intraductal papillary mucinous neoplasias (IPMNs) are pr

142 etter for noninvasive compared with invasive intraductal papillary mucinous neoplasm (84.5% vs. 36%;

143 ts (72%) and in small (</=30 mm) branch-duct intraductal papillary mucinous neoplasm (BD IPMN; 67%),

144 l consensus guidelines for the management of intraductal papillary mucinous neoplasm (IPMN) and mucin

145 e examined the possible relationship between intraductal papillary mucinous neoplasm (IPMN) and the d

146 uidelines for management of branch duct (BD) intraductal papillary mucinous neoplasm (IPMN) espouse s

147 ted with main pancreatic duct (MPD)-involved intraductal papillary mucinous neoplasm (IPMN) has been

148 to malignancy of pancreatic branch-duct (BD) intraductal papillary mucinous neoplasm (IPMN) is infreq

149 and mucin staining were similar to those of intraductal papillary mucinous neoplasm (IPMN) of the pa

150 reatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN) precursor

151 The existing Intraductal Papillary Mucinous Neoplasm (IPMN) risk stra

152 Human intraductal papillary mucinous neoplasm (IPMN) specimens

153 Moreover, cystic lesions resembling intraductal papillary mucinous neoplasm (IPMN) were obse

154 of 34 Chronic Pancreatitis (CP), 71 PDAC, 70 intraductal papillary mucinous neoplasm (IPMN), 16 mucin

155 arcinoma (PDAC) and its preneoplastic lesion intraductal papillary mucinous neoplasm (IPMN), to find

156 Intraductal papillary mucinous neoplasm (IPMN)-derived p

157 or recurrence after pancreatic resection for intraductal papillary mucinous neoplasm (IPMN).

158 ic diseases such as chronic pancreatitis and intraductal papillary mucinous neoplasm (IPMN).

159 ic resection for adenocarcinoma arising from intraductal papillary mucinous neoplasm (IPMN).

160 sence of invasive carcinoma in patients with intraductal papillary mucinous neoplasm (IPMN).

161 Intraductal papillary mucinous neoplasm (particularly th

162 premalignant (mucinous cystic neoplasm =16, intraductal papillary mucinous neoplasm = 5, neuroendocr

163 neuroendocrine tumors = 4), or 10 malignant (intraductal papillary mucinous neoplasm = 7, cystadenoca

164 between SCA and premalignant mucinous cysts (intraductal papillary mucinous neoplasm [IPMN], mucinous

165 ssessment of guidelines for the treatment of intraductal papillary mucinous neoplasm and cystic lesio

166 Intraductal papillary mucinous neoplasm and pancreatic n

167 -term survival after resection of pancreatic intraductal papillary mucinous neoplasm and to correlate

168 guidelines for mucinous cystic neoplasm and intraductal papillary mucinous neoplasm are superior to

169 pancreatic surgery, only one patient with an intraductal papillary mucinous neoplasm had high-grade d

170 However, the progression of intraductal papillary mucinous neoplasm of the pancreas

171 Intraductal papillary mucinous neoplasm patients appear

172 Invasive intraductal papillary mucinous neoplasm recurs frequentl

173 In contrast, noninvasive intraductal papillary mucinous neoplasm recurs infrequen

174 ic cancer, specific mutations, and high-risk intraductal papillary mucinous neoplasm, as they are at

175 l benign, whereas mucinous cystic neoplasms, intraductal papillary mucinous neoplasm, cystic neuroend

176 In invasive intraductal papillary mucinous neoplasm, recurrence was

177 3CA, and FGF6 were more commonly detected in intraductal papillary mucinous neoplasm-associated PDACs

178 e, that Tif1gamma and Smad4 both regulate an intraductal papillary mucinous neoplasm-to-PDAC sequence

179 rmed mainly for neuroendocrine tumors (35%), intraductal papillary mucinous neoplasms (33%), solid ps

180 outcomes between adenocarcinoma arising from intraductal papillary mucinous neoplasms (A-IPMN) and pa

181 tic neoplasms (adenoma 28, borderline 7), 22 intraductal papillary mucinous neoplasms (adenoma 9, bor

182 Currently, most patients with branch duct intraductal papillary mucinous neoplasms (BD-IPMN) are o

183 ime for surveillance of low-risk branch duct intraductal papillary mucinous neoplasms (BD-IPMNs) has

184 pancreatic cysts, especially for branch duct intraductal papillary mucinous neoplasms (BD-IPMNs), rem

185 s known about the development of branch duct intraductal papillary mucinous neoplasms (BD-IPMNs).

186 The histopathologic heterogeneity of intraductal papillary mucinous neoplasms (IPMN) complica

187 a large single-center population of resected intraductal papillary mucinous neoplasms (IPMN) of the p

188 l consensus guidelines for the management of intraductal papillary mucinous neoplasms (IPMN) recommen

189 ogression following resection for pancreatic intraductal papillary mucinous neoplasms (IPMN) using ta

190 ductal adenocarcinoma (PDAC) may arise from intraductal papillary mucinous neoplasms (IPMN) with mal

191 (1.8%): 12 pseudocysts, 2 cysts/remnants, 4 intraductal papillary mucinous neoplasms (IPMN), 2 adeno

192 dilation following pancreatoduodenectomy for intraductal papillary mucinous neoplasms (IPMN).

193 ttle is known about the origin of pancreatic intraductal papillary mucinous neoplasms (IPMN).

194 atic neuroendocrine tumors (PanNET, n = 42), intraductal papillary mucinous neoplasms (IPMN, n = 20),

195 GNAS-activating mutations are reported in intraductal papillary mucinous neoplasms (IPMNs) and in

196 Intraductal papillary mucinous neoplasms (IPMNs) and muc

197 lly-detected cystic PDAC precursors known as intraductal papillary mucinous neoplasms (IPMNs) and pre

198 Among PCNs, Intraductal Papillary Mucinous Neoplasms (IPMNs) are com

199 Pancreatic intraductal papillary mucinous neoplasms (IPMNs) are gro

200 Intraductal papillary mucinous neoplasms (IPMNs) are pan

201 Intraductal papillary mucinous neoplasms (IPMNs) are the

202 nsus Guidelines, the diagnostic criterion of intraductal papillary mucinous neoplasms (IPMNs) involvi

203 profiles of mixed-type and branch-duct (BD) intraductal papillary mucinous neoplasms (IPMNs) is impo

204 Intraductal papillary mucinous neoplasms (IPMNs) of the

205 The molecular pathology of intraductal papillary mucinous neoplasms (IPMNs) of the

206 Intraductal papillary mucinous neoplasms (IPMNs) of the

207 ad use and advances in radiographic imaging, Intraductal Papillary Mucinous Neoplasms (IPMNs) of the

208 inoma may be encountered in association with intraductal papillary mucinous neoplasms (IPMNs) of the

209 The natural history of intraductal papillary mucinous neoplasms (IPMNs) remains

210 e analyze proteins and glycoproteins from 64 intraductal papillary mucinous neoplasms (IPMNs), 55 cys

211 ging have resulted in increased detection of intraductal papillary mucinous neoplasms (IPMNs), and th

212 stic cyst types: serous cystadenomas (SCAs), intraductal papillary mucinous neoplasms (IPMNs), mucino

213 isting management guidelines for branch-duct intraductal papillary mucinous neoplasms (IPMNs).

214 to inform better counseling of patients with intraductal papillary mucinous neoplasms (IPMNs).

215 ients with mucinous cystic neoplasms (n=17), intraductal papillary mucinous neoplasms (n=15), serous

216 , including 3 node-negative R0 microinvasive intraductal papillary mucinous neoplasms (without recurr

217 ted neoplasms were identified in 85 HRIs (82 intraductal papillary mucinous neoplasms and 3 pancreati

218 n had high-grade dysplasia in less than 3 cm intraductal papillary mucinous neoplasms and in multiple

219 ression of Kras(G12D) leads to predominantly intraductal papillary mucinous neoplasms and mucinous cy

220 onitored clinically, mucinous cysts, such as intraductal papillary mucinous neoplasms and mucinous cy

221 More cases of intraductal papillary mucinous neoplasms are being diagn

222 Intraductal papillary mucinous neoplasms are increasingl

223 Intraductal papillary mucinous neoplasms are the most co

224 ctively reviewed and classified 113 resected intraductal papillary mucinous neoplasms as invasive car

225 Intraductal papillary mucinous neoplasms can be multifoc

226 enes that could contribute to progression of intraductal papillary mucinous neoplasms into malignanci

227 Intraductal papillary mucinous neoplasms of the bile duc

228 e mucinous cystic neoplasms of the liver and intraductal papillary mucinous neoplasms of the bile duc

229 l features of invasive carcinomas arising in intraductal papillary mucinous neoplasms of the pancreas

230 Intraductal papillary mucinous neoplasms of the pancreas

231 explore the prevalence of CBD dilatation in Intraductal Papillary Mucinous Neoplasms of the pancreas

232 (1.9%) had high-risk lesions (ie, high-grade intraductal papillary mucinous neoplasms or grade 3 panc

233 plasms-related tumors (4/58, 6.9%) than non- intraductal papillary mucinous neoplasms PDAC (5/385, 1.

234 Intraductal papillary mucinous neoplasms represent a dis

235 t models for predicting malignant pancreatic intraductal papillary mucinous neoplasms were developed

236 a and high-risk precursor neoplasms, such as intraductal papillary mucinous neoplasms with high-grade

237 as, high-grade dysplasia, or intestinal-type intraductal papillary mucinous neoplasms with intermedia

238 ing cystic tumors (mucinous cystic neoplasms+intraductal papillary mucinous neoplasms) from benign cy

239 aracterize malignant potential (for example, intraductal papillary mucinous neoplasms).

240 had pancreatic ductal adenocarcinoma, 17 had intraductal papillary mucinous neoplasms, 26 had symptom

241 obtained cyst fluid samples of 169 PCLs (90 intraductal papillary mucinous neoplasms, 43 mucinous cy

242 tory of the most common subtype, branch-duct intraductal papillary mucinous neoplasms, are not clearl

243 Some cysts, such as intraductal papillary mucinous neoplasms, mucinous cysti

244 ses of tissue and cyst fluid from pancreatic intraductal papillary mucinous neoplasms, the monoclonal

245 les; we found dMMR in a larger proportion of intraductal papillary mucinous neoplasms-related tumors

246 2D) oncogene in the mouse pancreas to induce intraductal papillary mucinous neoplasms.

247 strategy in the management of patients with Intraductal Papillary Mucinous Neoplasms.

248 s mutations in the pancreas of patients with intraductal papillary mucinous tumors (IPMT) and to anal

249 rare "medullary" variant of adenocarcinoma, intraductal papillary mucinous tumors are observed in pa

250 Intraductal papillary mucinous tumors continue to be com

251 Intraductal papillary mucinous tumors of the pancreas ha

252 Two of 11 intraductal papillary mucinous tumors were positive for

253 of large intraductal stones, localization of intraductal papillary mucinous tumors, and localization

254 y and differentiation between ductal type of intraductal papillary mucinous tumors.

255 f exosomes in the serum of healthy subjects, intraductal papillary mucosal neoplasms and pancreatic d

256 nd of the usually rare BTC precursor lesion, intraductal papillary neoplasia (18.3%).

257 Intraductal papillary neoplasm of the bile duct (IPNB) i

258 Intraductal papillary neoplasm of the biliary tract (B-I

259 ience with mucinous ductal ectasia (MDE) and intraductal papillary neoplasms (IPNs) and to compare th

260 Intraductal papillary neoplasms with or without MDE repr

261 Despite the growing awareness of intraductal papillary-mucinous neoplasms (IPMNs) of the

262 Intraductal papillary-mucinous neoplasms (IPMNs) of the

263 Intraductal papillary-mucinous tumor (IPMT) of the pancr

264 rize gene expression profiles in a series of intraductal papillary-mucinous tumors (IPMTs) of the pan

265 The encompessing term intraductal papillary-mucinous tumors is appropriate.

266 Fifty-seven percent were found to have intraductal papilloma as the source of discharge, with f

267 c follow-up showed no residual lesion in 10, intraductal papilloma in 14, intraductal papillomatosis

268 defect was performed; results were a benign intraductal papilloma in each, with atypia in one.

269 enign, and 22 matched those of corresponding intraductal papillomas that were involved by or were sep

270 t of displaced cells, usually originating in intraductal papillomas.

271 l lesion in 10, intraductal papilloma in 14, intraductal papillomatosis in two, papilloma with adjace

272 nd 15 (16%) (P > .99); and cribriform and/or intraductal PCa in 14 (15%) and 13 (14%) (P > .99).

273 ree, impaired stem cell potential, disrupted intraductal polarity, and loss of tissue function.

274 nomas are thought to arise from noninvasive, intraductal precursor lesions called pancreatic intraepi

275 ed to arise from histologically identifiable intraductal precursors [pancreatic intraepithelial neopl

276 DL, which has been associated with decreased intraductal pressure and fewer bile infarcts.

277 Atypical intraductal proliferation (AIP) is considered a borderli

278 e were mainly observed in areas of intensive intraductal proliferation and high tumor cell density.

279 pithelial neoplasia (HGPIN), a pre-malignant intraductal proliferation that can be mistaken as IDC-P,

280 appropriately viewed as an early neoplastic intraductal proliferation.

281 By exploiting an intraductal retrovirus (RCAS)-mediated gene delivery met

282 Intraductal RFA, via both endoscopic and percutaneous ap

283 s in breast-duct anatomy limit the degree of intraductal spread and explain much of the substantial a

284 Our models suggest that intraductal spread and fusing of lesions drive our obser

285 n the left hepatic lobe with the presence of intraductal stones and dilatation of intrahepatic ducts.

286 mice and human salivary ductal cells, while intraductal stones were detected in both mice (TRPC3(-/-

287 nal chronic pancreatitis, treatment of large intraductal stones, localization of intraductal papillar

288 ed CDDD11-8 also inhibited growth of mammary intraductal TNBC xenograft tumours with no overt toxicit

289 Intraductal trypsin, in subinflammatory concentrations,

290 ed hyperplasia is reversible until extensive intraductal vascularization occurs, but continued progre

291 s an endoscopic tool that can provide direct intraductal visualisation and facilitate therapeutic man

292 invasive transition of breast tumors in the intraductal xenograft model.

293 phenotype in 3D triple-negative cultures and intraductal xenografts by sustaining expression of E-cad

294 We conclude that intraductal xenografts model ER + BC dormancy and reveal

295 We compare intraductal xenografts of ER(+) and triple-negative (TN)